On January 11, 2024, Ji Xing Pharmaceuticals (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, announced the acquisition of BIIB131 from Biogen for clinical development. Wilson Sonsini Goodrich & Rosati advised JIXING on the transaction.

BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.

Under the terms of the agreement, JIXING will acquire the program for an undisclosed upfront with potential milestones and royalties on global sales.

The Wilson Sonsini team that advised JIXING on the transaction included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; senior counsel Kimberley Biagioli; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.

For more information, please see JIXING’s news release.